AI Committee
Global Network of Top Medical and Technology Collaborations
International Precision Medical Technology Co., Ltd. is a leading international healthcare company headquartered in Los Angeles, California, United States, a global hub of advanced medical practices. We are committed to providing customers with personalized genetic testing, gene editing, and customized health products, as well as the integration of traditional Chinese and Western medicine diagnosis and treatment methods, to promote the innovation and development of global healthcare.
The members of AI Committee
Dr. Li is a partner and director of medical education at Boomerang Healthcare and a visiting clinical professor at Stanford University's Pain Center. He specializes in pain management and regenerative medicine for clients including professional athletes and Silicon Valley executives. Dr. Li has published more than 20 articles in international journals and has spoken at several international conferences. He has participated in several clinical trials and has been featured in several media outlets. He is the Chief Medical Officer of iHealth Frontier, dedicated to optimizing the administration of healthcare in the United States and serves as Vice President of the World Association of Chinese Physicians. Dr. Li has a medical background from Zhejiang University School of Medicine and Peking Union Medical University, as well as a Ph.D. in pharmacology from the University of Florida. He completed his residency and specialist training in pain at Harvard and Stanford Universities and serves as an independent director of EDOC Acquisition Corp.
Li, Gang The Director of AI Committee. Co-founder, former President and former Board Chairman of The Society of Chinese American Physician Entrepreneurs (SCAPE).
Dr. Jiang is a highly accomplished biotech executive with extensive leadership experience across major pharmaceutical companies and startups. Most recently, he served as President of BioMap US, overseeing data science, drug target identification, and antibody drug development. Trained initially as a pathologist at PUMC hospital, Dr. Jiang earned his Ph.D. in Genome Sciences from the University of Washington. His unique blend of clinical medicine and genomics expertise positions him as a leader in applying data science to accelerate drug development. Previously, Dr. Jiang held pivotal roles including Executive Director at Gilead Sciences and Senior Computational Biologist at Genentech. With a strong focus on leveraging data sciences and AI. Dr. Jiang's translational research efforts have led to the approval of over ten medicines across autoimmune diseases, virology, and oncology, and he has authored numerous impactful scientific publications.
Jiang, Zhaoshi Vice President of Bioinformatics and formerly Executive Director of Bioinformatics and Data Science at Gilead Sciences.
Dr. Liu received his Master of Clinical Medicine in the Department of Radiology from Peking Union Medical College (PUMC) from 1984-1987, his Master of Molecular and Cell Biology from Eastern Michigan University from 1990-1992, and his ABNM certification in 2000. As the NM service representative for DC VAMC's internal and external strategic planning plans and multiple rounds, responsible for the management, protocol, and quality assurance of comprehensive NM imaging and treatment services for VAMC 24x7 in Washington, DC, including PET/CT, SPECT/CT, D-SPECT, DEXA, clinical trials, research, etc. Cardiology researcher training, teleradiology at Martinsburg and Beckley. To investigate the clinical role of interpretations of PET/CT, MPI, general/emergency NM studies, DEXA, and radioisotope therapy. Won the 2006 Nuclear Medicine Society, GE Visiting Physician, China Lecturer Award, and successfully held lectures in PUMC Hospital, Beijing Cancer Institute and Xuzhou Hospital Center.
Liu, Ming M.D., Director of the Center for Nuclear Medicine at the Veterans Affairs Hospital in Washington, D.C.
Dr. Yu graduated from Nanjing University School of Medicine and completed his AP/CP pathology residency and dermatopathology fellowship at the University of Michigan. He then served as an assistant professor of pathology at the University of New Mexico and as a staff pathologist at Diagnostic Pathology Medical Group in California. In 2015, Dr. Yu joined Beaumont Hospital and Oakland University in Michigan, where he was the medical director of pathology informatics and a staff dermatopathologist at Beaumont Health System. After earning his master’s degree in computer science, he contributed to various commercial and academic projects. Later, as Director of Pathology at PathAI, Dr. Yu led a team of pathologists supporting AI algorithm development for translational research and diagnostic pathology. Dr. Yu is the founder of HiPatho, a company dedicated to empowering pathologists through advanced AI technologies.
Yu, Limin Doctor, HiPatho Founder.
Dr. Peng received his PhD from the National University of Defense Technology from 1997 to 2008, and participated in the joint doctoral training program at the City University of Hong Kong from 2007 to 2008. He served as the director of the Life Science Division of Tianhe Supercomputer at the National University of Defense Technology from 2008 to 2017. In 2017, he served as the Deputy Director of the National Supercomputing Center in Hunan University. He currently holds the position of adjunct professor at the National University of Defense Technology and continues the Deputy Director of the National Supercomputing Center in Changsha. His research interests encompass high-performance computing, bioinformatics, big data, and blockchain. He serves as an Executive editor and deputy editor of several international journals. At the same time, he has held significant academic positions both domestically and internationally.
Peng, Shaoliang Chairman of Hunan Biomedical Engineering Society, National Supercomputing Changsha Center (Hunan University), Changjiang Scholar.
Professor Wei has made pioneering contributions across various interdisciplinary fields, notably providing the first theoretical proof of the existence of ferroelectric liquid crystals, the first revelation of the microscopic mechanism of explosion reaction and the discovery and verification of the anti-aging effect of xanthin. Currently, his research focuses on bioinformatics research, systematic molecular simulation, AI-assisted drug design, and enzyme directed evolution research based on artificial intelligence. Meanwhile, He investigated the key technologies of high-throughput drug discovery large model based on massive multi-source heterogeneous biomedical multi-modal big data. The closed-loop research of dry and wet experiments was realized under the dual drive of high-throughput drug big data and artificial intelligence. By applying modern computational drug design methods and databases of active ingredients from traditional Chinese medicine, They has successfully designed and developed antiviral drug candidates for diseases and Alzheimer's disease.
Wei, Dongqing Professor of School of Life Sciences and State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, Professor of Pengcheng National Laboratory, Director of Qihe Laboratory, President of Zhongjing Chinese Medicine Industry Research Institute.
Dr. Wang mainly studies the latent and activation mechanism of herpes virus, the host immune response and various symptoms caused by herpes virus infection. He is currently working at Mount Sinai Hospital in Los Angeles as a project scientist and laboratory manager. In addition to project research, paper publication and fund application, I am also responsible for managing the operation of the entire laboratory, including personnel training, laboratory consumables procurement, etc. Familiar with key experimental skills ranging from DNA, RNA, proteins, cells to model animals, as well as hands-on and data analysis experience in recent biotechnology developments such as stem cell culture, single cell sequencing, etc. He has published more than 30 articles in various SCI journals to date. ARVO member; Member of the editorial Board of Frontiers in Immunology.
Wang, Shaohui B.S. in Biology, Nankai University, Ph.D. in Molecular Biology, Shanghai Institute of Biochemistry, Chinese Academy of Sciences.
Professor Xie's work has been exhibited frequently at museums and galleries in the United States and around the world, with recent solo shows including "Evidence" (2019-20) at the Asia Society Museum in New York and "Spotlight" (2017-18) at the Denver Art Museum. Xie Xiaoze's works have received extensive attention and praise from professional and mainstream media, including American Art, Art News magazine, The New York Times, and the Toronto Globe and Mail. His works are in the collections of many museums and cultural institutions. Xie has received the Asia Society Northern California Division's "Asia Maker Award" (2022), the Third Nanjing International Fine Art Exhibition Painting Academic Award (2016), the Joann Mitchell Foundation Painter and Sculptor Award (2013), the Pollock-Krasner Foundation Award (2003), And artist awards at the Dallas Art Museum and the Phoenix Art Museum.
Xie, Xiaoze An internationally renowned artist, currently serving as a Chair Professor in the Department of Art and Art History at Stanford University in the United States.
At NVIDIA, she works on Graph Neural Networks (GNNs) and generative AI research and applications for drug discovery, LLM and fraud detections. She earned her Ph.D. in computer science in 2020 and M.S. in statistics in 2015 from the University of California, Davis. She got her B.S. in applied mathematics from the Sun Yat-Sen University in 2013. She is interested in Graph Neural Networks, generative AI high-performance computing in Machine Learning, and Adversarial Machine Learning. She has publications on Neurips, ICML, SIGKDD, HPEC, etc. And she has been reviewers for SIGKDD, Neurocomputing, Neurips, TKDD, TNNLS and other journals.
Wang, Xiaoyun The Senior Applied Scientist at NVIDIA.
Lily Batta M.d., Director of the Transplant Center at Maryland Hospital.
